Exscientia CEO Andrew Hopkins at EUBIO22 (Rachel Kiki for Endpoints News)

Bris­tol My­ers pass­es on two Ex­sci­en­tia on­col­o­gy can­di­dates, but biotech to move them in­to clin­ic next year

Ex­sci­en­tia said it ex­pand­ed its pipeline Tues­day morn­ing, but the biotech is do­ing so with­out the help of a years­long part­ner: Bris­tol My­ers Squibb.

The Big Phar­ma has de­cid­ed not to move for­ward with two on­col­o­gy de­vel­op­ment can­di­dates, Ex­sci­en­tia said. The AI-dri­ven UK biotech plans to start test­ing the com­pounds in the clin­ic next year on its own, CEO An­drew Hop­kins told End­points News.

“We took this as part of a rou­tine port­fo­lio pri­or­i­ti­za­tion hap­pen­ing in BMS and oth­er Big Phar­ma at the mo­ment,” Hop­kins said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.